The Time Is Right For Trials Of Multidrug-Resistant TB Therapy

Main Category: Tuberculosis
Also Included In: Respiratory / Asthma;  Clinical Trials / Drug Trials
Article Date: 05 Nov 2007 - 17:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 stars

4 (1 votes)

Healthcare Prof:5 stars

5 (1 votes)


Drug-resistant TB strains may account for 10% of the 8 million new cases of TB that occur each year, say Carole Mitnick (Harvard Medical School, Boston, USA) and colleagues. Increasing concern about resistance has redoubled interest in strategies to control drug-resistant TB, they say, especially in settings of high HIV prevalence.

Current treatments for MDR-TB last between 18 and 24 months, adverse effects are common, and many patients cannot be cured.

However, the time is now right, say Mitnick and colleagues, to conduct randomized clinical trials of new regimens for treating MDR-TB. For a start, MDR-TB treatment programs have expanded dramatically: 40 programs in resource-limited settings are managing treatment for nearly 30,000 patients. These treatment programs provide the settings in which trials can be implemented. In addition, for the first time in 30 years, several new drug classes hold promise for MDR-TB treatment.

"Four elements are needed," say the authors, "to make MDR-TB treatment trials a reality: money; additional work on the drug pipeline; rigorous, interdisciplinary preclinical work on individual agents and regimens; and an understanding that TB clinical trials need not be a zero-sum endeavor."

Citation: Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W (2007) Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 4(11): e292.
Please click here

About PLoS Medicine

PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues.

http://www.plosmedicine.org

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource.

Public Library of Science
185 Berry Street, Suite 3100
San Francisco, CA 94107
USA

Article adapted by Medical News Today from original press release.
Visit our tuberculosis section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
PLOS EMB. "The Time Is Right For Trials Of Multidrug-Resistant TB Therapy." Medical News Today. MediLexicon, Intl., 5 Nov. 2007. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/87446.php>

APA
PLOS EMB. (2007, November 5). "The Time Is Right For Trials Of Multidrug-Resistant TB Therapy." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/87446.php.

Please note: If no author information is provided, the source is cited instead.


Tuberculosis

Most Popular Articles



Follow Our Tuberculosis News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Tuberculosis Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »